.png)
Liposomal Doxorubicin – Advancing Targeted Cancer Treatment
Liposomal doxorubicin represents a significant advancement in oncology, offering a more targeted and less toxic alternative to conventional chemotherapy. By encapsulating doxorubicin within liposomes, this formulation enhances drug delivery directly to tumor cells while minimizing exposure to healthy tissues. This approach improves therapeutic outcomes and reduces side effects commonly associated with traditional chemotherapy.
The increasing prevalence of cancer worldwide has driven the adoption of more effective and patient-friendly treatments. Liposomal formulations allow for prolonged circulation time in the bloodstream, enabling better accumulation in tumor sites through enhanced permeability and retention (EPR) effects. This results in improved efficacy, especially in treating breast cancer, ovarian cancer, and Kaposi’s sarcoma.